Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
01:04pm, Wednesday, 09'th Nov 2022 Benzinga
SVB Leerink raised MannKind Corporation (NASDAQ: MNKD) price target from $5 to $6. . SVB Leerink analyst Thomas Smith maintained the stock with an Outperform rating. MannKind shares rose 5% to close
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
12:02pm, Wednesday, 09'th Nov 2022
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript
04:00am, Wednesday, 09'th Nov 2022 The Motley Fool
EBS earnings call for the period ending September 30, 2022.
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
12:55am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Emergent BioSolutions Inc. (EBS) Q3 2022 Earnings Call Transcript
09:47pm, Tuesday, 08'th Nov 2022
Emergent BioSolutions Inc. (NYSE:EBS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
09:16pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2022.
Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates
09:04pm, Tuesday, 08'th Nov 2022
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
11:45pm, Monday, 07'th Nov 2022 Zacks Investment Research
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
08:05pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvant
Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst
02:05pm, Monday, 24'th Oct 2022
These top small-cap stocks to buy present daring investors with significant upside. Fundamentally, companies with a relatively diminutive profile typically command higher growth potential.
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
10:30am, Tuesday, 18'th Oct 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
06:30am, Tuesday, 18'th Oct 2022
GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial r
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
02:13pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
08:12pm, Monday, 26'th Sep 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincid
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
02:12pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
